WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $64,653,826 | $109,630,169 | $205,778,387 | $339,352,085 |
| - Cash | $8,279,182 | $9,669,839 | $6,395,222 | $9,003,280 |
| + Debt | $4,939,849 | $4,561,359 | $4,421,661 | $4,295,287 |
| Enterprise Value | $61,314,493 | $104,521,689 | $203,804,826 | $334,644,092 |
| Revenue | $18,675,371 | $17,034,255 | $15,268,660 | $10,290,050 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Gross Profit | $7,650,820 | $6,827,901 | $6,724,014 | $4,828,897 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| EBITDA | $6,429,039 | $5,501,667 | $6,222,827 | $4,514,093 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |
| Net Income | $3,356,081 | $3,399,729 | $4,420,286 | $3,388,478 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| % Growth | 1.3% | -23.8% | 31.2% | – |
| Operating Cash Flow | $5,217,257 | $4,667,712 | $5,541,673 | $3,431,258 |
| Capital Expenditures | -$3,929,621 | -$4,230,514 | -$5,868,390 | -$6,523,114 |
| Free Cash Flow | $1,287,636 | $437,198 | -$326,717 | -$3,091,856 |